SciELO - Scientific Electronic Library Online

 
vol.93 númeroNSPE1Ingresos pediátricos asociados a infección por SARS-CoV-2 en un prestador de saludCaracterísticas de la infección por SARS-CoV-2 en niños y adolescentes asistidos durante el primer año de la pandemia en un prestador privado de salud de Montevideo índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Links relacionados

Compartir


Archivos de Pediatría del Uruguay

versión impresa ISSN 0004-0584versión On-line ISSN 1688-1249

Resumen

DE LOS ANGELES, Teresa et al. Description of the activities carried out by the Honorary Commission for the Fight against Tuberculosis and Prevalent Diseases (CHLA-EP) within the COVID-19 2021 vaccination strategy. Arch. Pediatr. Urug. [online]. 2022, vol.93, n.nspe1, e217.  Epub 01-Jun-2022. ISSN 0004-0584.

Since 1946, the Honorary Commission for the Fight against Tuberculosis and Prevalent Diseases (CHLA-EP), controls Tuberculosis and Diseases Preventable by Vaccination. The vaccination of children, adolescents and adults is carried out regularly, through campaigns or special days, and it has achieved excellent coverage and control of vaccine-preventable diseases. The CHLA-EP includes the Immunization Operational Program and the logistics of conservation and distribution of the vaccines in its A. Calmette Laboratory. In the COVID-19 Vaccination Strategy, it participated in the logistics, distribution, training and selection of the personnel who would carry out vaccination, supervision of cold chain standards and safe vaccination activities.

Objective:

describe the CHLA-EP work within the National Vaccination Plan COVID-19’s Strategy.

Material and methods:

descriptive analysis of the CHLA-EP reports and communication as well as reports from the Epidemiology Division of the Ministry of Public Health (MSP).

Results:

1) Review and training on the vaccines being developed and arriving to Uruguay: Pfizer BioNtech, CoronaVac, Oxford AZ; characteristics and action mechanisms, efficacy/effectiveness, side effects, target population, costs, use of personal protective equipment;

2) Provision of the vaccines’ warehousing site, conservation and storage, cold chain and distribution national strategies as the characteristics of each biological product and required training to achieve a solid and seamless cold chain;

3) Planning: weekly strategy meetings with the Immunization Unit of the Ministry of Public Health as well as with government members. Survey of existing vaccination clinics, creation of COVID vaccination clinics, provision of human and material resources, new contracts, survey of priority individuals regarding their risk of acquiring COVID and dying (long-stay facilities and caregivers, hemodialysis patients, complex heart diseases, transplant recipients, patients with low mobility, carriers of Down Syndrome, haemato-oncological, diabetic, obese patients);

4) Training by roles (registration staff and vaccinators, vaccine preparers, administrators, job references, backup), training in vial handling and dosage (via zoom at country level), participation in a PAHO training course;

5) Support/advertising material and audiovisual media: COVID-19 Campaign Logo design, presentations for training and updating, audiovisual material, technical sheets for platforms, post-vaccination observation sheets, quick guides for the registration and saving of vaccination agreements, labels and identification design and materials differentiation for the Pfizer vaccine, video tutorial for the download and correct use of APP VA-QMed. Since the beginning of the SARS CoV 2 pandemic in 2020, the CHLA-EP organized, planned, executed and supervised different activities (E.g.: the 2020 campaign against Influenza) before the COVID-19 Vaccination Strategy that began on 2/27/21, it was universal (people> 12 years of age), fast and safe. As of 6/19/21, 61% of the population received one dose and 39% had received two.

Conclusions:

the CHLA-EP is the organizational and executive agency for national vaccination campaigns, it acts in coordination with its different structures (vaccinators-vaccination sites, Calmette Laboratory). In 2021, it contributed to the success of the MSP’s COVID-19 Vaccination Strategy.

Palabras clave : COVID-19 vaccine; Local health strategies; Uruguay; COVID-19.

        · resumen en Español | Portugués     · texto en Español     · Español ( pdf )